.jpg "Acceleron Pharma (NASDAQ: XLRN)")
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Acceleron Pharma (XLRN – Research Report), Prothena (PRTA – Research Report) and AstraZeneca (AZN – Research Report).
Acceleron Pharma (XLRN)
In a report released today, Kennen MacKay from RBC Capital maintained a Hold rating on Acceleron Pharma, with a price target of $179.00. The company’s shares closed last Friday at $167.65, close to its 52-week high of $174.24.
According to TipRanks.com, MacKay is a 5-star analyst with an average return of
Acceleron Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $164.80.
See today’s analyst top recommended stocks >>
Prothena (PRTA)
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Prothena, with a price target of $100.00. The company’s shares closed last Friday at $75.32, close to its 52-week high of $78.95.
According to TipRanks.com, Olson is a 4-star analyst with an average return of
Currently, the analyst consensus on Prothena is a Strong Buy with an average price target of $80.67, a 3.4% upside from current levels. In a report issued on September 17, Cantor Fitzgerald also maintained a Buy rating on the stock with a $103.00 price target.
AstraZeneca (AZN)
In a report released today, Andrew Berens from Leerink Partners maintained a Buy rating on AstraZeneca, with a price target of $73.00. The company’s shares closed last Friday at $60.35, close to its 52-week high of $61.30.
According to TipRanks.com, Berens is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AstraZeneca with a $70.30 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XLRN:
- TotalEnergies, Safran Join Hands to Reduce CO2 Emissions
- Monday’s Pre-Market: Here’s What You Need to Know Before the Market Opens
- Intel Invests $20B in Two New Chip Factories in Arizona
- JMP Securities Sticks to Its Buy Rating for Evelo Biosciences (EVLO)
- Pfizer, Opko’s BLA for Pediatric GHD Treatment Extended
